Hematologic Diseases

Expanding access to hematopoietic stem cell transplants for patients in need

Program
Pre-Clinical
Phase 1
Phase 2
Phase 3
Commercial

  • BMT Comparative Study

    Phase 2
    0
    I
    II
    III
    IV

    A multi-phase, multi-center clinical trial of partially HLA-mismatched (>4/8), unrelated bone marrow for transplantation to treat hematologic malignancies (MDS, AML, CLL, ALL, etc.). The study will compare the effectiveness of mismatched Ossium HPC, Marrow to live donor haploidentical transplants.

    Related Products

    HPC, Marrow

    Partners

    NMDP / Be the Match / CIBMTR

  • Micro Bone Marrow Transplants

    Pre-Clinical
    0
    I
    II
    III
    IV

    We are developing a safety and feasibility clinical trial for blood cancers where patients will receive a reduced (‘micro’) conditioning regimen and a mismatched bone marrow transplant using Ossium HPC, Marrow.

    Related Products

    HPC, Marrow

    Partners

    Columbia University

Organ Transplant Rejection

Allowing organ transplant recipients to lead healthy lives without immunosuppression

Program
Pre-Clinical
Phase 1
Phase 2
Phase 3
Commercial

  • Multivisceral Transplantation

    Phase 2
    0
    I
    II
    III
    IV

    Phase 1b/2a safety and feasibility clinical trial with the objective of inducing tolerance in intestinal transplant patients by establishing mixed chimerism via infusion of Ossium’s selected CD34+ cells processed from the organ donor's bone marrow.

    Related Products

    Selected CD34+ Cells

    Partners

    Columbia University

  • Upper Extremity (vascular composite allografts)

    Phase 2
    0
    I
    II
    III
    IV

    Phase 2 clinical trial with the objective of inducing a tolerogenic state after vascularized composite allotransplantation (VCA) of upper extremities via infusion of HPC, Marrow processed from the VCA donor.

    Related Products

    HPC, Marrow

    Partners

    Johns Hopkins University

Diseases of Inflammation

Modulating immune function and inflammation to treat diseases characterized by the presence of an inflammatory component

Program
Pre-Clinical
Phase 1
Phase 2
Phase 3
Commercial

  • Crohn's Disease, Pouch Fistula

    Phase 2
    0
    I
    II
    III
    IV

    Phase 1b/2a clinical trial determining the effectiveness of a perilesional injection of 100 million BM-MSCs for the treatment of refractory pouch fistula Crohn’s disease (PFCD)

    Related Products

    MSCs

    Partners

    Cleveland Clinic

  • Crohn's Disease, Perianal Fistula

    Phase 2
    0
    I
    II
    III
    IV

    A Phase 1b/2a study of culture-expanded adult allogeneic bone marrow derived mesenchymal stem cells (MSCs) for the treatment of refractory perianal fistulizing Crohn’s disease.

    Related Products

    MSCs

    Partners

    Cleveland Clinic

  • Graft-versus-Host Disease (GVHD)

    Phase 1
    0
    I
    II
    III
    IV

    Open-label, non-randomized Phase 1b clinical trial evaluating the use of interferon gamma-primed MSCs to prevent graft-versus-host disease in adult and pediatric patients undergoing hematopoietic cell transplantation (HCT) for acute leukemia and myelodysplastic syndromes

    Related Products

    MSCs

    Partners

    Emory University

  • Asthma

    Phase 1
    0
    I
    II
    III
    IV

    Phase 1 safety and efficacy clinical trial evaluating the use of interferon gamma-primed MSCs in children with moderate-to-severe persistent asthma.

    Related Products

    MSCs

    Partners

    Children's Healthcare of Atlanta

Partner with Us

Let's work together to revolutionize treatment for patients suffering from hematologic diseases, organ transplant rejection, and diseases of inflammation.